Biotechnology

ENA Respiratory appoints GSK veteran Melissa Faris to its board, a strategic move signaling an accelerated push for its innovative virus-agnostic nasal spray.

A novel RNA vaccine targeting hidden cancer antigens gets UK approval for a clinical trial, offering new hope for patients with hard-to-treat ovarian cancer.

Canadian giant Apotex acquires Cumberland's U.S. branded drugs for $100M, a move that expands its hospital presence and pivots Cumberland to a biotech.

Backed by military funding, a novel protein therapy that actively grows bone has finished a key clinical trial, promising to revolutionize dental surgery.

Korean brand Dr. Reju-All's pharmacist-led approach and PDRN science captivated nearly 5,000 dermatologists, signaling a new wave in U.S. skincare.

A new T-cell therapy, RPTR-1-201, enters clinical trials, offering hope for hard-to-treat solid tumors by targeting a shared, multi-cancer marker.

RIMAN rallies 2,000 in Macau, unveiling a $3M bio-material and a bold strategy to dominate the competitive APAC K-beauty direct selling market.

TGA approves Minjuvi, a dual-targeted immunotherapy for relapsed follicular lymphoma, offering a breakthrough option beyond traditional chemotherapy.

After nine years of success, a renewed pact between Novonesis and Biocodex aims to dominate the booming global probiotics market. Here's what it means.

The life sciences advisory firm adds a heavy-hitter with $150B+ in deal experience, signaling ambitious growth and a new focus on the Southeast.

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

Breakthrough trial data shows a new device can keep donor hearts viable for longer, potentially expanding the organ pool and saving thousands on waitlists.

As its leaders vie for a top entrepreneurial award, a look at how GenScript quietly became an indispensable engine for global scientific breakthroughs.

A new AI-powered skin patch test for psoriasis just got a major US approval, promising to end costly trial-and-error treatments for millions of patients.

A breakthrough review validates harnessing neutrophils, the immune system's foot soldiers, for cancer, with a new therapy now heading to human trials.

New TempLock™ tech in the SherpaPak® system aims to keep donor hearts stable longer, potentially expanding the reach of life-saving transplants.

A new peer-reviewed study shows MECART cleanrooms cut emissions by 33%, challenging industry standards with verifiable data and a circular design.

LifeSci Advisors' hire of finance and IR veteran Matthew Osborne signals a strategic push amid a competitive market and a rebounding biotech IPO landscape.

A novel gene therapy using precision-guided vectors could offer a one-time treatment for wet AMD, a leading cause of blindness, freeing patients from injections.

For the 5th straight year, WA's life sciences outpace job growth. See how AI leadership and strategic investment fuel its $43.4B economic impact.